Country: United States
Language: English
Source: NLM (National Library of Medicine)
NORGESTIMATE (UNII: C291HFX4DY) (NORGESTIMATE - UNII:C291HFX4DY), ETHINYL ESTRADIOL (UNII: 423D2T571U) (ETHINYL ESTRADIOL - UNII:423D2T571U)
Proficient Rx LP
PRESCRIPTION DRUG
Tri-Lo-Sprintec® (norgestimate and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy [see Clinical Studies (14)] . Do not prescribe Tri-Lo-Sprintec to women who are known to have the following conditions: There is little or no increased risk of birth defects in women who inadvertently use COCs during early pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb reduction defects) following exposure to low dose COCs prior to conception or during early pregnancy. Do not administer COCs to induce withdrawal bleeding as a test for pregnancy. Do not use COCs during pregnancy to treat threatened or habitual abortion. Advise the nursing mother to use other forms of contraception, when possible, until she has weaned her child. COCs can reduce milk production in breastfeeding mothers. This is less likely to occur once breastfeeding is well-established; howev
Tri-Lo-Sprintec® 28 (norgestimate and ethinyl estradiol tablets USP) is packaged in pouches of one blister card (NDC: 71205-287-28). Each of the 7 gray tablets contains 0.18 mg of the progestational compound, norgestimate, USP together with 0.025 mg of the estrogenic compound, ethinyl estradiol, USP and available as round, film-coated, biconvex, unscored tablets, debossed with stylized b on one side and 451 on the other side; Each of the 7 light blue tablets contains 0.215 mg of the progestational compound, norgestimate, USP together with 0.025 mg of the estrogenic compound, ethinyl estradiol, USP and available as round, film-coated, biconvex, unscored tablets, debossed with stylized b on one side and 452 on the other side; Each of the 7 blue tablets contains 0.25 mg of the progestational compound, norgestimate, USP together with 0.025 mg of the estrogenic compound, ethinyl estradiol, USP and available as round, film-coated, biconvex, unscored tablets, debossed with stylized b on one side and 453 on the other side. The 7 placebo tablets are white, round, biconvex, unscored, placebo tablets, debossed with stylized b on one side and 208 on the other side. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. PROTECT FROM LIGHT. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.
Abbreviated New Drug Application
TRI-LO-SPRINTEC- NORGESTIMATE AND ETHINYL ESTRADIOL PROFICIENT RX LP ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE TRI-LO-SPRINTEC SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR TRI-LO-SPRINTEC. TRI-LO-SPRINTEC (NORGESTIMATE/ETHINYL ESTRADIOL) TABLETS FOR ORAL USE INITIAL U.S. APPROVAL: 1989 WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ • • RECENT MAJOR CHANGES Contraindications (4) 08/2017 Warnings and Precautions (5.3) 08/2017 INDICATIONS AND USAGE Tri-Lo-Sprintec (norgestimate and ethinyl estradiol tablets) is an estrogen/progestin COC, indicated for use by women to prevent pregnancy. (1.1) DOSAGE AND ADMINISTRATION • • • DOSAGE FORMS AND STRENGTHS Tri-Lo-Sprintec (norgestimate and ethinyl estradiol tablets USP) is available in a blister card. Each blister card contains 28 tablets in the following order (3): • • • • CONTRAINDICATIONS • • • • • • WARNINGS AND PRECAUTIONS • • • • • ® TRI-LO-SPRINTEC IS CONTRAINDICATED IN WOMEN OVER 35 YEARS OLD WHO SMOKE. (4) CIGARETTE SMOKING INCREASES THE RISK OF SERIOUS CARDIOVASCULAR EVENTS FROM COMBINATION ORAL CONTRACEPTIVES (COC) USE. (4) ® Take one tablet daily by mouth at the same time every day. (2.2) Take tablets in the order directed on the blister pack. (2.2) Do not skip or delay tablet intake. (2.2) 7 gray tablets containing 0.18 mg norgestimate and 0.025 mg ethinyl estradiol 7 light blue tablets containing 0.215 mg norgestimate and 0.025 mg ethinyl estradiol 7 blue tablets containing 0.25 mg norgestimate and 0.025 mg ethinyl estradiol 7 white tablets (inert) A high risk of arterial or venous thrombotic diseases (4) Liver tumors or liver disease (4) Undiagnosed abnormal uterine bleeding (4) Pregnancy (4) Breast cancer or other estrogen- or progestin-sensitive cancer (4) Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir Read the complete document